Inhibitory effect of somatostatin analogue octreotide on the expression of p53 and Ras in human gastric cancer.
- Author:
Lei TIAN
1
;
Shu LI
Author Information
- Publication Type:Journal Article
- MeSH: Adenocarcinoma; drug therapy; metabolism; surgery; Adult; Aged; Antineoplastic Agents; therapeutic use; Female; Humans; Male; Middle Aged; Octreotide; therapeutic use; Proto-Oncogene Proteins p21(ras); genetics; metabolism; Somatostatin; analogs & derivatives; Stomach Neoplasms; drug therapy; metabolism; surgery; Tumor Suppressor Protein p53; genetics; metabolism
- From: Journal of Southern Medical University 2011;31(7):1245-1248
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the inhibitory effect of somatostatin (SST) analogue octreotide on human gastric cancer.
METHODSFifty gastric cancer patients were randomly assigned into 2 equal groups. The patients in the control group received no medication before surgical resection of gastric cancer, and those in octreotide group were given daily subcutaneous injection of 100 µg octreotide for 7 days before the surgery. The resected specimens were examined histologically and the expressions of p53 and Ras protein were detected by immunohistochemistry.
RESULTSCompared with the control group, gastric cancer tissue in octreotide group showed significantly increased necrosis (P<0.05) and enhanced proliferation of fibrous tissues (P<0.05) with lowered expressions of p53 and Ras protein (P<0.05).
CONCLUSIONOctreotide can inhibit the expressions of p53 and Ras and suppress the growth of the human gastric cancer.
